Combination Sitravatinib and Nivolumab Boosts Outcomes in Advanced Kidney Cancer

In patients with advanced clear cell renal cell carcinoma, an optimal sitravatinib dose combined with a fixed dose of nivolumab improved outcomes in a phase 1-2 trial.
Reuters Health Information

source https://www.medscape.com/viewarticle/972855?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?